Ebele Iloabachie
Psychiatric/Mental Health · Fairview Heights, ILNPI 1093050841
Payments from drug & device makers
Across 256 payments — averaging $16.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Otsuka America Pharmaceutical, Inc.$588
- E.r. Squibb & Sons, L.L.C.$329
- Lundbeck LLC$235
- Neurocrine Biosciences, Inc.$210
- plus $627 from 10 others
What the payments were for
- Food & beverage$4,270100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 87 | $1,262 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 63 | $1,019 |
| Otsuka America Pharmaceutical, Inc. | 36 | $588 |
| E.r. Squibb & Sons, L.L.C. | 10 | $329 |
| Lundbeck LLC | 14 | $235 |
| Neurocrine Biosciences, Inc. | 13 | $210 |
| Johnson & Johnson | 9 | $176 |
| Axsome Therapeutics, Inc. | 5 | $105 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $87 |
| Teva Pharmaceuticals USA, Inc. | 3 | $51 |
| Vanda Pharmaceuticals Inc. | 2 | $49 |
| Idorsia Pharmaceuticals US Inc | 3 | $47 |
| Tris Pharma Inc | 3 | $46 |
| Alkermes, Inc. | 2 | $36 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
| Adlon Therapeutics L.p. | 1 | $14 |
How this compares
$4,270 in reported general payments places this provider in the 90th percentile of 922 psychiatric/mental health providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lurasidone Hcl | 16 | $6,618 |
| Duloxetine Hcl | 63 | $1,727 |
| Olanzapine | 16 | $719 |
| Aripiprazole | 34 | $707 |
| Buspirone Hcl | 35 | $631 |
| Mirtazapine | 21 | $624 |
| Escitalopram Oxalate | 29 | $551 |
| Lamotrigine | 32 | $499 |
| Hydroxyzine Hcl | 12 | $445 |
| Divalproex Sodium | 16 | $437 |
| Bupropion XlBupropion Hcl | 15 | $374 |
| Trazodone Hcl | 33 | $306 |
| Propranolol Hcl | 16 | $210 |
| Lorazepam | 42 | $206 |
| Clonazepam | 38 | $191 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Fairview Heights
- Erin PetrusicChicago$517K
- Maurice BrownleeChicago$162K
- Melissa VitaleChicago$151K
- Alan AmbergChicago$119K
- Jaime MendozaMaryville$111K
- Jennifer TheryMaryville$83K
- Carole Weddington HuntGranite City$67K
- Jessica WhelanBloomington$55K
- Lynn LochnerKankakee$41K
- Julie CarbrayChicago$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.